Corrigendum: Subcutaneous and sublingual immunotherapy in allergic asthma in children [Front Pediatr, 5, (2017) (82)] DOI: 10.3389/fped.2017.00082;Subcutaneous and sublingual immunotherapy in allergic asthma in children

Frontiers in Pediatrics

Volumn 5, Issue , 2017, Pages

  Tsabouri, Sophia ^a   Mavroudi, Antigoni ^b   Feketea, Gavriela ^c   Guibas, George V ^d,e  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Amaliada Hospital Unit   (Greece)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Allergy; Asthma; Children; Subcutaneous immunotherapy; Sublingual immunotherapy

Indexed keywords

EID: 85033226455     PISSN: None     EISSN: 22962360     Source Type: Journal    
DOI: 10.3389/fped.2017.00187     Document Type: Erratum

References (96)

1. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J (2008) 31(1):143-78. doi:10.1183/09031936.00138707
2. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy (2008) 63(Suppl 86):8-160. doi:10.1111/j.1398-9995.2007.01620.x
3. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol (2011) 127(1 Suppl):S1-55. doi:10.1016/j.jaci.2010.09.034
4. Burks AWC, Casale MA, Cox T, Demoly P, Jutel M, Nelson H, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol (2013) 131(5): 1288-96. e3. doi:10.1016/j.jaci.2013.01.049
5. Akdis CA, Akdis M. Mechanisms and treatment of allergic disease in the bigpicture of regulatory T cells. J Allergy Clin Immmunol (2009) 123:735-46. doi:10.1016/j.jaci.2009.02.030
6. Akdis CA. Therapies for allergic inflammation: refining strategies to induce tolerance. Nat Med (2012) 18(5):736-49. doi:10.1038/nm.2754
7. Passalacqua G, Nowak-Wegrzyn A, Canonica GW. Local side effects of sublingual and oral immunotherapy. J Allergy Clin Immunol Pract (2017) 5(1):13-21. doi:10.1016/j.jaip.2016.06.020
8. Bousquet J, Lockey R, Malling H. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol (1998) 102:558-62. doi:10.1016/S0091-6749(98)70271-4
9. Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International Consensus on Allergen Immunotherapy II: mechanisms, standardization, and pharmacoeconomics. J Allergy Clin Immunol (2016) 137(2):358-68. doi:10.1016/j.jaci.2015.12.1300
10. Creticos P, Esch R, Couroux P, Gentile D, D'Angelo P, Whitlow B, et al. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol (2014) 133:751-8. doi:10.1016/j.jaci.2013.10.041
11. Passalacqua G, Canonica GW. Allergen immunotherapy: history and future developments. Immunol Allergy Clin North Am (2016) 36(1):1-12. doi:10.1016/j.iac.2015.08.001
12. Frew AJ. Hundred years of allergen immunotherapy. Clin Exp Allergy (2011) 41:1221-5. doi:10.1111/j.1365-2222.2011.03768.x
13. Puggioni F, Durham SR, Francis JN. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. Allergy (2006) 60:678-84. doi:10.1111/j.1398-9995.2005.00762.x
14. Stewart GE, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol (1992) 90(4 Pt I):567-78. doi:10.1016/0091-6749(92)90129-P
15. Canonica GW, Bousquet J, Casale T, Lockey R, Baena-Cagnani C, Pawankar R, et al. Sublingual Immunotherapy. World Allergy Organ J (2009) 2(11):223-81. doi:10.1097/WOX.0b013e3181c6c379
16. Malling HJ. Sublingual immunotherapy: efficacy-methodology and outcome of clinical trials. Allergy (2006) 61(Suppl 81):24-8. doi:10.1111/j.1398-9995. 2006.01158.x
17. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy (2005) 60(1):4-12. doi:10.1111/j.1398-9995.2005.00699.x
18. Allam JP, Wurtzen PA, Reinartz M, Winter J, Vrtala S, Chen KW, et al. Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties. J Allergy Clin Immunol (2010) 126(3): 638-45.e1. doi:10.1016/j.jaci.2010.04.039
19. van de Veen W, Stanic B, Wirz OF, Jansen K, Globinska A, Akdis M. Role of regulatory B cells in immune tolerance to allergens and beyond. J Allergy Cli Immunol (2016) 138(3):654-65. doi:10.1016/j.jaci.2016.07.006
20. Shamji MH, Durham SR. Mechanisms of immunotherapy to aeroallergens. Clin Exp Allergy (2011) 41(9):1235-46. doi:10.1111/j.1365-2222.2011. 03804.x
21. Braza F, Chesne J, Durand M, Dirou S, Brosseau C, Mahay G, et al. A regulatory CD9(+) B-cell subset inhibits HDM-induced allergic airway inflammation. Allergy (2015) 70(11):1421-31. doi:10.1111/all.12697
22. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immmunol (2011) 127:18-27. doi:10.1016/j.jaci.2010.11.030
23. Evans R, Pence H, Kaplan H, Rocklin RE. The effect of immunotherapy on humoral and cellular responses in ragweed hayfever. J Clin Invest (1976) 57(5):1378-85. doi:10.1172/JCI108406
24. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immmunol (2004) 113:1025-34. doi:10.1016/j.jaci.2004.03.024
25. Fujita H, Soyka MB, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. Clin Transl Allergy (2012) 2:1-8. doi:10.1186/2045-7022-2-2
26. Hanci D, Sahin E, Muluk NB, Cingi C. Immunotherapy in all aspects. Eur Arch Otorhinolaryngol (2016) 273(6):1347-55. doi:10.1007/s00405-015-3553-5
27. Bousquet J, Schunemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C, et al. Allergic rhinitis and its impact on asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 130(5):1049-62. doi:10.1016/j.jaci.2012.07.053
28. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunolgy. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol (2007) 120(3 Suppl):S25-85. doi:10.1016/j.jaci.2007.06.019
29. Passalacqua G, Melioli G, Bonifazi F, Bonini S, Maggi E, Senna G, et al. The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy. Allergy (2013) 68(8):1029-33. doi:10.1111/all.12194
30. Canonica GW, Ansotegui IJ, Pawankar R, Schmid-Grendelmeier P, van Hage M, Baena-Cagnani CE, et al. A WAO-ARIA-GA(2)LEN consensus document on molecular-based allergy diagnostics. World Allergy Organ J (2013) 6(1):17. doi:10.1186/1939-4551-6-17
31. Matricardi PM. Molecular profile clustering of IgE responses and potential implications for specific immunotherapy. Curr Opin Allergy Clin Immunol (2013) 13(4):438-45. doi:10.1097/ACI.0b013e3283630ca5
32. Stringari G, Tripodi S, Caffarelli C, Dondi A, Asero R, Di Rienzo Businco A, et al. The effect of component-resolved diagnosis on specific immunotherapy prescription in children with hay fever. J Allergy Clin Immunol (2014) 134(1):75-81. doi:10.1016/j.jaci.2014.01.042
33. Arshad SH. An update on allergen immunotherapy. Clinical Med (Lond) (2016) 16(6):584-7. doi:10.7861/clinmedicine.16-6-584
34. Calderon MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol (2011) 127(1):30-8. doi:10.1016/j.jaci.2010.08.024
35. Pajno GB, Bernardini R, Peroni D, Arasi S, Martelli A, Landi M, et al. Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report. Ital J Pediatr (2017) 43(1):13. doi:10.1186/s13052-016-0315-y
36. Pitsios C, Demoly P, Bilo MB, Gerth van Wijk R, Pfaar O, Sturm GJ, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy (2015) 70(8):897-909. doi:10.1111/all.12638
37. Scadding GW, Calderon MA, Bellido V, Koed GK, Nielsen NC, Lund K, et al. Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. J Immunol Methods (2012) 384(1-2):25-32.doi:10.1016/j.jim.2012.06.013
38. Calderon MA, Simons FER, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy (2012) 67:302-11. doi:10.1111/j.1398-9995. 2011.02761.x
39. Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P, et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (öGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int (2014) 23(8):282-319. doi:10.1007/s40629-014-0032-2
40. Stelmach I, Sobocinska A, Majak P, Smejda K, Jerzynska J, Stelmach W. Comparison of the long-term efficacy of 3-and 5-year house dust mite allergen immunotherapy. Ann Allergy Asthma Immunol (2012) 109(4):274-8. doi:10.1016/j.anai.2012.07.015
41. Frati F, Dell'Albani I, Incorvaia C. Long-term efficacy of allergen immunotherapy: what do we expect? Immunotherapy (2013) 5(2):131-3. doi:10.2217/imt.12.154
42. Eifan AO, Akkoc T, Yildiz A, Keles S, Ozdemir C, Bahceciler NN, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy (2010) 40(6):922-32. doi:10.1111/j.1365-2222.2009.03448.x
43. Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol (2012) 157(3):288-98. doi:10.1159/000327566
44. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol (2010) 126(5):969-75. doi:10.1016/j.jaci.2010.08.030
45. Karakoc-Aydiner E, Eifan AO, Baris S, Gunay E, Akturk E, Akkoc T, et al. Long-term effect of sublingual and subcutaneous immunotherapy in dust mite-allergic children with asthma/rhinitis: a 3-year prospective randomized controlled trial. J Investig Allergol Clin Immunol (2015) 25(5):334-42. Erratum in: J Investig Allergol Clin Immunol (2016) 26(2):144
46. Ozdemir C, Yazi D, Gocmen I, Yesil O, Aydogan M, Semic-Jusufagic A, et al. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. Pediatr Allergy Immunol (2007) 18(6):508-15. doi:10.1111/j.1399-3038.2007.00549.x
47. Canonica GW, Compalati E. Year in review: allergen immunotherapy. Ann Allergy Asthma Immunol (2015) 114(3):173-4. doi:10.1016/j.anai.2014.12.024
48. Anolik R, Schwartz AM, Sajjan S, Allen-Ramey F. Patient initiation and persistence with allergen immunotherapy. Ann Allergy Asthma Immunol (2014) 113(1):101-7. doi:10.1016/j.anai.2014.04.008
49. Arroabarren E, Tabar AI, Echechipía S, Cambra K, García BE, Alvarez-Puebla MJ. Optimal duration of allergen immunotherapy in children with dust mite respiratory allergy. Pediatr Allergy Immunol (2015) 26(1):34-41. doi:10.1111/pai.12296
50. Pajno GB, Caminiti L, Crisafulli G, Vita D, Valenzise M, De Luca R, et al. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: a randomized controlled study. Pediatr Allergy Immunol (2011) 22(8):803-7. doi:10.1111/j.1399-3038. 2011.01196.x
51. Blumberga G, Groes L, Haugaard L, Dahl R. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy (2006) 61(7):843-8. doi:10.1111/j.1398-9995.2006.01088.x
52. Maestrelli P, Zanolla L, Pozzan M, Fabbri LM. Regione Veneto Study Group on the 'Effect of immunotherapy in allergic A. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite'. J Allergy Clin Immunol (2004) 113(4):643-9. doi:10.1016/j.jaci.2003.12.586
53. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev (2010) (8):CD001186. doi:10.1002/14651858.CD001186.pub2
54. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. Clin Ther (2000) 22(3):329-41. doi:10.1016/S0149-2918(00)80037-5
55. Olaguíbel JM, álvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Invest Allergol Clin Immunol (2005) 15(1):9-16
56. Kim JM, Lin SY, Suarez-Cuervo C, Chelladurai Y, Ramanathan M, Segal JB, et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Pediatrics (2013) 131(6):1155-67. doi:10.1542/peds.2013-0343
57. Passalacqua G. Specific immunotherapy in asthma: a comprehensive review. J Asthma (2014) 51(1):29-33. doi:10.3109/02770903.2013.853082
58. Saporta D. Efficacy of sublingual immunotherapy versus subcutaneous injection immunotherapy in allergic patients. J Environ Public Health (2012) 2012:492405. doi:10.1155/2012/492405
59. Demoly P, Passalacqua G, Calderon MA, Yalaoui T. Choosing the optimal dose in sublingual immunotherapy: rationale for the 300 index of reactivity dose. Clin Transl Allergy (2015) 5:44. doi:10.1186/s13601-015-0088-1
60. Rodríguez-Pérez N, Ambriz-Moreno Mde J, Canonica GW, Penagos M. Frequency of acute systemic reactions in patients with allergic rhinitis and asthma treated with sublingual immunotherapy. Ann Allergy Asthma Immunol (2008) 101(3):304-10. doi:10.1016/s1081-1206(10)60496-6
61. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy (2009) 64(11):1570-9. doi:10.1111/j.1398-9995.2009.02129.x
62. James C, Bernstein DI. Allergen immunotherapy: an updated review of safety. Curr Opin Allergy Clin Immunol (2017) 17(1):55-9. doi:10.1097/ACI.0000000000000335
63. Yukselen A. Allergen-specific immunotherapy in pediatric allergic asthma. Asia Pac Allergy (2016) 6(3):139-48. doi:10.5415/apallergy.2016.6.3.139
64. Yukselen A, Kendirli SG. Role of immunotherapy in the treatment of allergic asthma. World J Clin Cases (2014) 2(12):859-65. doi:10.12998/wjcc.v2.i12.859
65. Rodríguez Del Río P, Vidal C, Just J, Tabar AI, Sanchez-Machin I, Eberle P, et al. The European survey on adverse systemic reactions in allergen immunotherapy (EASSI): a paediatric assessment. Pediatr Allergy Immunol (2017) 28(1):60-70. doi:10.1111/pai.12660
66. Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol (2015) 136(3):556-68. doi:10.1016/j.jaci.2015.04.047
67. Passalacqua G, Durham RS; Global Allergy and Asthma European Network. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immmunol (2007) 119:881-91. doi:10.1016/j.jaci.2007.01.045
68. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narku A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium absorbed six-grass allergoid. Allergy (2005) 60:801-7. doi:10.1111/j.1398-9995.2005.00790.x
69. Jutel M, Jaeger L, Suck R, Meyer H, Math D, Fiebig H, et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immmunol (2005) 116:608-13. doi:10.1016/j.jaci.2005.06.004
70. Seidenberg J, Pajno GB, Bauer CP, La Grutta S, Sieber J. Safety and tolerability of seasonal ultra-rush, high-dose sublingual-swallow immunotherapy in allergic rhinitis to grass and tree pollens: an observational study in 193 children and adolescents. J Investig Allergol Clin Immunol (2009) 19(2):125-31
71. Calderon MA, Larenas D, Kleine-Tebbe J, Jacobsen L, Passalacqua G, Eng PA, et al. European Academy of Allergy and Clinical Immunology task force report on 'dose-response relationship in allergen-specific immunotherapy'. Allergy (2011) 66(10):1345-59. doi:10.1111/j.1398-9995.2011.02669.x
72. Duric-Filipovic I, Caminati M, Kostic G, Filipovic D, Zivkovic Z. Allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis. World J Pediatr (2016) 12(3):283-90. doi:10.1007/s12519-016-0022-1
73. Harmanci K, Razi CH, Toyran M, Kanmaz G, Cengizlier MR. Evaluation ofnew sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. Asian Pac J Allergy Immunol (2010) 28(1):7-13
74. Inal A, Altintas DU, Yilmaz M, Karakoc GB, Kendirli SG, Sertdemir Y. Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. J Investig Allergol Clin Immunol (2007) 17(2):85-91
75. Niggemann B, Jacobsen L, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy (2006) 61(7):855-9. doi:10.1111/j.1398-9995.2006.01068.x
76. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy (2007) 62(8):943-8. doi:10.1111/j.1398-9995.2007.01451.x
77. Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol (2004) 114(4):851-7. doi:10.1016/j.jaci.2004.07.012
78. Marogna M, Tomassetti D, Bernasconi A, Colombo F, Massolo A, Di Rienzo Businco A, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol (2008) 101:206-11. doi:10.1016/S1081-1206(10)60211-6
79. Zolkipli Z, Roberts G, Cornelius V, Clayton B, Pearson S, Michaelis L, et al. Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood. J Allergy Clin Immunol (2015) 136(6):1541-7.e1-11. doi:10.1016/j.jaci.2015.04.045
80. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy (2006) 61(2):198-201. doi:10.1111/j.1398-9995. 2006.01011.x
81. Finegold I. Immunotherapy: when to initiate treatment in children. Allergy Asthma Proc (2007) 28(6):698-705. doi:10.2500/aap.2007.28.3053
82. Zuberbier T, Bachert C, Bousquet PJ, Passalacqua G, Walter Canonica G, Merk H, et al. GA(2) LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy (2010) 65(12):1525-30. doi:10.1111/j.1398-9995.2010.02474.x
83. Bernstein DI, Wanner M, Borish L, Liss GM; Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol (2004) 113(6):1129-36. doi:10.1016/j.jaci.2004.02.006
84. Jutel M. Allergen-specific immunotherapy in asthma. Curr Treat Options Allergy (2014) 1:213-9. doi:10.1007/s40521-014-0013-1
85. Nelson HS. Multiallergen immunotherapy for allergic rhinitis and asthma. J Allergy Clin Immunol (2009) 123(4):763-9. doi:10.1016/j.jaci.2008.12.013
86. Kopp MV, Hamelmann E, Bendiks M, Zielen S, Kamin W, Bergmann KC, et al. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy. Pediatr Allergy Immunol (2013) 24(5):427-33. doi:10.1111/pai.12098
87. Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy ClinImmunol (2002) 109(2):274-80. doi:10.1067/mai.2002.121949
88. Braido F, Corsico A, Rogkakou A, Ronzoni V, Baiardini I, Canonica GW. The relationship between allergen immunotherapy and omalizumab for treating asthma. Expert Rev Respir Med (2015) 9(2):129-34. doi:10.1586/17476348.2 015.1000866
89. Chelladurai Y, Suarez-Cuervo C, Erekosima N, Kim JM, Ramanathan M, Segal JB, et al. Effectiveness of subcutaneous versus sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. J Allergy Clin Immunol Pract (2013) 1(4):361-9. doi:10.1016/j.jaip.2013.04.005
90. Nelson HS, Makatsori M, Calderon MA. Subcutaneous immunotherapy and sublingual immunotherapy: comparative efficacy, current and potential indications, and warnings-United States versus Europe. Immunol Allergy Clin North Am (2016) 36(1):13-24. doi:10.1016/j.iac.2015.08.005
91. Carr TF, Bleecker E. Asthma heterogeneity and severity. World Allergy Organ J (2016) 9(1):41. doi:10.1186/s40413-016-0131-2
92. Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, et al. Sublingual immunotherapy: world allergy organization position paper 2013 update. World Allergy Organ J (2014) 7(1):6. doi:10.1186/1939-4551-7-6
93. Keles S, Karakoc-Aydiner E, Ozen A, Izgi AG, Tevetoglu A, Akkoc T, et al. A novel approach in allergen-specific immunotherapy: combination of sublingual and subcutaneous routes. J Allergy Clin Immunol (2011) 128(4):808-15. e7. doi:10.1016/j.jaci.2011.04.033
94. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy (2006) 61(Suppl 82):1-20. doi:10.1111/j.1398-9995.2006.01219_1.x
95. Jutel M, Bartkowiak-Emeryk M, Breborowicz A, Cichocka-Jarosz E, Emeryk A, Gawlik R, et al. Sublingual immunotherapy (SLIT)-indications, mechanism, and efficacy. Ann Agric Environ Med (2016) 23:44-53. doi:10.5604/12321966.1196851
96. Berto P, Frati F, Incorvaia C. Economic studies of immunotherapy: a review. Curr Opin Allergy Clin Immunol (2008) 8(6):585-9. doi:10.1097/ACI.0b013e32831411e9